What 476 APOE4 Carriers Tried for Their Brain Health, and What Their Data Revealed
A real-world analysis of 30,737 biomarker readings, revealing what improved, what did not, and which intervention patterns repeated.
Key takeaways · TL;DR
A real-world analysis of 30,737 biomarker readings, revealing what improved, what did not, and which intervention patterns repeated.
Hi Phoenix friend,
When you get your APOE4 result, you go looking for answers.
What you usually find is noise.
Reddit threads. Facebook groups. Hundreds of replies from people with a different genotype, age, health history, and starting point. Half of the advice contradicts the other half.
You close the tab more anxious than when you opened it.
I know because I did the same thing in December 2024, the week I learned that I carry two copies of APOE4.
I did not want another confident opinion. I wanted to know what APOE4 carriers were actually trying, when they started, and what happened to their health afterward.
So I built Phoenix.
What 476 APOE4 carriers found
Today, we published Phoenix APOE4 Research: The Beat the Odds Study. Release 001.
More than 675 APOE4 carriers now call Phoenix home. The 476 members who joined before the report’s data cutoff form the cohort behind Release 001.
Together, they contributed:
30,737 biomarker readings
176 observations where an intervention and a biomarker moved together in a healthier direction
The report covers:
What members tried for their brain health, and what happened to their biomarkers afterward
Individual before-and-after cases with the complete recorded protocol
Intervention patterns that appeared across multiple members
Findings that stayed relatively stable or moved in an unfavorable direction
The methods, data gaps, and limits behind the analysis
One member’s LDL fell from 263 to 78 mg/dL in 70 days while taking ezetimibe and psyllium. That was the largest lipid change in Release 001.
We show that result because it matters.
We also show the disappointing findings because they matter just as much.
What this report can, and cannot, tell us
Release 001 contains real-world observational evidence.
It is not a randomized clinical trial. It cannot prove that an intervention caused a specific result.
Members may change several things at once. Follow-up times differ. Not every member has repeat bloodwork. Some repeated groups remain small. Lifestyle, medication, weight, diet, and other factors can affect the same biomarker.
This means the report does not tell us what universally “works for APOE4.”
It tells us:
What happened in this cohort
Which results repeated across more than one person
Where members appeared to respond differently
Which ideas deserve more careful testing
Where the data is still too thin to support a conclusion
That is already more useful than a collection of anonymous anecdotes.
The goal is not to make weak data sound certain. The goal is to make the next release stronger.
Why one carrier can never answer this alone
I am a Doctor of Pharmacy.
When I started testing interventions on myself, I approached it the way I was trained to: change one variable, wait three months, measure the result, then move to the next variable.
I did the math.
Testing my entire stack that way would take decades. It is impossible to do alone.
Phoenix spreads that work across hundreds of carriers.
Each member still runs their own experiment.
But when members record their baseline, start date, protocol, daily changes, and repeat measurements, we can compare similar cases.
We can ask:
Did the same pattern appear in anyone else?
What was different between responders and non-responders?
Did someone make the same change without seeing the same result?
Which intervention is the most plausible contributor?
What should we measure next?
Phoenix cannot magically remove confounding when someone changes five or ten things at once.
It can narrow the likely contributors. It can show where a signal repeats. It can separate an isolated story from a pattern worth investigating. And it can give you ideas on what to test next.
A member who recently joined described it as:
“You’re kind of running really small clinical trials within the community.”
These are not clinical trials in the formal sense. But the phrase captures the idea.
Many structured self-experiments become more useful when we learn from them together.
You do not need to start from zero
You should not blindly copy what worked for another member.
Their result can help you decide what question to test. Your own data must provide the answer.
That process starts with:
A clear baseline
An exact intervention start date
A complete record of what changed
Consistent tracking
A repeat measurement
Every completed experiment adds to your personal response profile.
Suppose your LDL falls substantially after starting ezetimibe. That result does not, by itself, prove that you are a cholesterol hyper-absorber. It may suggest that cholesterol absorption is an important pathway for you and deserves closer examination.
That is more useful than simply recording that “ezetimibe worked.”
The real question is:
What does this response teach us about your biology, and what should you test next?
Over time, Phoenix aims to help distinguish between:
Strong responders
Partial responders
Non-responders
People who respond only under certain conditions
The goal is not to find one universal APOE4 protocol.
It is to learn which intervention may help which person, under which conditions.
Joining Phoenix helps you find and validate what works for you AND make this APOE4 research stronger
Release 002 becomes stronger when more carriers:
Record their intervention start dates
Log the complete protocol
Track changes consistently
Complete repeat bloodwork
Report results that did not improve
Follow comparable protocols
476 carriers built Release 001.
Every carrier who joins and completes that process helps make Release 002 more precise, both for themselves and for the next carrier searching for answers.
Help the right people find this
The more members running experiments, the stronger the insights for everyone. Help us strengthen our research by sending Release 001 to:
One APOE4 carrier who is still trying to decide what to measure
A clinician who wants to understand what carriers are doing
A researcher who should see the evidence system this community is building
One thoughtful share to the right person matters more than a hundred passive likes.
Cheers,
Kevin
P.S. You do not need two copies of APOE4 to join Phoenix. APOE3/4 and APOE2/4 carriers are already part of the community and the study cohort.
I am also moving to San Francisco to raise mission-aligned capital to recruit more APOE4 carriers, build research partnerships, strengthen the team. For a relevant introduction, email me at kevin@thephoenix.community.
